遗传性肾脏补体疾病
本综述概述了近20年补体系统异常驱动的遗传性肾脏病,重点讨论与aHUS和C3优势型肾小球病强相关的基因,包括补体因子H、补体成分3、补体因子H相关蛋白,以及仅与aHUS相关的补体因子B、补体因子I和膜辅蛋白。文中还强调了关键问题与挑战,并指出未来方向。
要点
- 补体系统异常是aHUS和C3优势型肾小球病的重要遗传基础
- 已发现多个基因与疾病强相关,推动创新疗法出现并改善预后
- 遗传诊断和补体靶向治疗是未来重要方向
核心结论
- 过去20年对补体异常所致遗传性肾病认识显著进步,部分创新疗法已改善患者结局。
研究设计与样本
- 综述,聚焦单基因(孟德尔)补体驱动的aHUS和C3优势型肾小球病。
主要发现
- 与aHUS和C3优势型肾小球病均强相关的基因包括补体因子H、补体成分3、补体因子H相关蛋白。
- 仅与aHUS强相关的基因包括补体因子B、补体因子I和膜辅蛋白。
临床怎么用
- 肾内科医生应关注补体遗传学在aHUS和C3优势型肾小球病诊断与治疗中的价值。
局限性
- 讨论限于与aHUS和C3优势型肾小球病强相关的特定基因,未涵盖其他补体相关疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past 20 years, we have witnessed tremendous advances in our ability to diagnose and treat genetic diseases of the kidney caused by complement dysregulation. Staggering progress was realized toward a better understanding of the genetic underpinnings and pathophysiology of many forms of atypical hemolytic uremic syndrome (aHUS) and C3-dominant glomerulopathies that are driven by complement system abnormalities. Many of these seminal discoveries paved the way for the design and characterization of several innovative therapies, some of which have already radically improved patients' outcomes. This review offers a broad overview of the exciting developments that have occurred in the recent past, with a particular focus on single-gene (or Mendelian), complement-driven aHUS and C3-dominant glomerulopathies that should be of interest to both nephrologists and kidney researchers. The discussion is restricted to genes with robust associations with both aHUS and C3-dominant glomerulopathies (complement factor H, complement component 3, complement factor H-related proteins) or only aHUS (complement factor B, complement factor I, and membrane cofactor protein). Key questions and challenges are highlighted, along with potential avenues for future directions.
引用
- Lemaire M, Noone D, Lapeyraque AL, et al. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol. 2021. PMID: 33536243. doi:10.2215/CJN.11830720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。